USA - NASDAQ:TXMD - US88338N2062 - Common Stock
The current stock price of TXMD is 1.29 USD. In the past month the price increased by 23.58%. In the past year, price decreased by -17.61%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 51.42 | 786.04B | ||
| JNJ | JOHNSON & JOHNSON | 18.32 | 458.09B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 18.75 | 258.18B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 14.78 | 253.17B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 13.73 | 236.64B | ||
| MRK | MERCK & CO. INC. | 11.39 | 218.99B | ||
| PFE | PFIZER INC | 7.3 | 140.75B | ||
| SNY | SANOFI-ADR | 11.72 | 125.63B | ||
| GSK | GSK PLC-SPON ADR | 9.62 | 86.71B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 6.49 | 88.95B | ||
| ZTS | ZOETIS INC | 23.56 | 64.93B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 50.06 | 44.26B |
TherapeuticsMD, Inc. operates as a pharmaceutical company. The company is headquartered in Boca Raton, Florida and currently employs 1 full-time employees. The company went IPO on 2001-01-31. The company receives royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company granted a license to commercialize IMVEXXY, BIJUVA, and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands and assigned its exclusive license to commercialize ANNOVERA to Mayne Pharma. IMVEXXY (estradiol vaginal inserts) pharmaceutical product is for the treatment of moderate-to-severe dyspareunia. BIJUVA pharmaceutical product is a Food and Drug Administration (FDA)-approved bioidentical hormone therapy combination of estradiol and progesterone in a single, oral capsule for the treatment of moderate-to-severe vasomotor symptoms due to menopause in women with a uterus. ANNOVERA pharmaceutical product is a one-year ring-shaped contraceptive vaginal system (CVS).
THERAPEUTICSMD INC
951 Yamato Road, Suite 220
Boca Raton FLORIDA 33431 US
CEO: Robert G. Finizio
Employees: 1
Phone: 15619611900
TherapeuticsMD, Inc. operates as a pharmaceutical company. The company is headquartered in Boca Raton, Florida and currently employs 1 full-time employees. The company went IPO on 2001-01-31. The company receives royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company granted a license to commercialize IMVEXXY, BIJUVA, and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands and assigned its exclusive license to commercialize ANNOVERA to Mayne Pharma. IMVEXXY (estradiol vaginal inserts) pharmaceutical product is for the treatment of moderate-to-severe dyspareunia. BIJUVA pharmaceutical product is a Food and Drug Administration (FDA)-approved bioidentical hormone therapy combination of estradiol and progesterone in a single, oral capsule for the treatment of moderate-to-severe vasomotor symptoms due to menopause in women with a uterus. ANNOVERA pharmaceutical product is a one-year ring-shaped contraceptive vaginal system (CVS).
The current stock price of TXMD is 1.29 USD. The price decreased by -1.53% in the last trading session.
TXMD does not pay a dividend.
TXMD has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
THERAPEUTICSMD INC (TXMD) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.05).
The outstanding short interest for THERAPEUTICSMD INC (TXMD) is 0.34% of its float.
ChartMill assigns a technical rating of 6 / 10 to TXMD. When comparing the yearly performance of all stocks, TXMD is a bad performer in the overall market: 73.29% of all stocks are doing better.
ChartMill assigns a fundamental rating of 4 / 10 to TXMD. The financial health of TXMD is average, but there are quite some concerns on its profitability.
Over the last trailing twelve months TXMD reported a non-GAAP Earnings per Share(EPS) of -0.05. The EPS increased by 91.26% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -1.19% | ||
| ROE | -1.68% | ||
| Debt/Equity | 0 |